

## Pleiotropic Multi-Drug Co-Assembled Nanocomposites Offer Protection Against Doxorubicin-Induced Cardiotoxicity [Corrigendum]


Yin D, Li C, Li J, et al. *Int J Nanomedicine*. 2025;20:9311–9326. <https://doi.org/10.2147/IJN.S528349>

The authors discovered that the incorrect image was used for **Figure 4C** PGPP/NPs+DOX on page 9319 of the published article. This error was unintentional and occurred during the figure assembly process. The authors take full responsibility for the oversight.

The Journal confirms that the error in **Figure 4C** PGPP/NPs+DOX does not affect the original experimental results, core research conclusions, or the editorial decision-making for the published manuscript if identified and declared at the time of submission. All underlying raw data and research findings of the article remain accurate and reliable.

The correct **Figure 4** is as follows.





**Figure 4** PGPP/NPs conferred protection to normal cells against DOX-induced cytotoxicity in vitro. **(A)** CLSM images and **(B)** Flow cytometry analysis of ROS expression in H9C2 cells after treating with PBS, DOX, GPP + DOX, PGPP + DOX, and PI + GI + PB + DOX (n = 3). Scale bars, 100  $\mu$ m. **(C)** LIVE-DEAD cell-staining of H9C2 cells after treating with PBS, DOX, DOX + GPP/NPs, and DOX + PGPP/NPs (Green: Live, Red: Dead). Scale bars, 100  $\mu$ m. **(D)** Cell viabilities of H9C2 incubated with Dox at IC50 value after preincubation with increasing concentrations of PGPP/NPs (n = 6). **(E)** CLSM images and **(F)** fluorescence quantification of LC3 expression in primary cardiomyocytes after treating with PBS, DOX, DOX + GPP/NPs, and DOX + PGPP/NPs (n = 3). Scale bars, 10  $\mu$ m. Flow cytometry results of the expression of **(G and H)** CD86 and **(I and J)** CD206 in RAW 264.7 cells after treating with PBS, LPS, PGPP/NPs, and LPS + PGPP/NPs (n = 3). Data are presented as the mean  $\pm$  SD. \**p* < 0.05; \*\**p* < 0.01; \*\*\**p* < 0.001; \*\*\*\**p* < 0.0001.